第17届世界肺癌大会(WCLC)将于12月4 日- 7日在奥地利维也纳举办。从今年开始,WCLC会议每年举行一次。本届会议的主题是“让我们一起战胜肺癌(WCLC 2016 Together against Lung Cancer)”。400多位世界知名专家将在WCLC 2016会议上担任讲者、专场主持和壁报讨论者;会议入选了300多项口头报告和mini口头报告,1700多项摘要作为壁报展示。本次会议还设置了国际肺癌研究协会(IASLC)、中国临床肿瘤学会(CSCO)以及中国肺癌防治联盟(CAALC)共同举办的联合论坛,Fred R. Hirsch、吴一龙和白春学教授担任联合论坛主席。广东省肺癌研究所吴一龙教授的CTONG 1201研究报告入选主席研讨会,我国肺癌领域的多位专家学者受邀在大会上发表主题报告、分享经验,详情如下。
WS02: IASLC Supporting the Implementation of Global CT Screening (Ticketed Session) - FULL
The Shanghai Screening Trial
上海的肺癌筛查试验
讲者:第二军医大学附属长征医院刘士远教授
时间:12月3日 13.30
地点:STRAUSS 1
(JCES01) Joint IASLC - Chinese Society for Clinical Oncology - Chinese Alliance Against Lung Cancer Session (Sign up Required)
IASLC、CSCO和CAALC共同举办的联合论坛
时间:12月4日 08:00 - 11:45
地点: Stolz 1
主持:Fred R. Hirsch教授、吴一龙教授、白春学教授
主要报告:
Perspectives on Precision Medicine for Early Stage NSCLC
复旦大学附属中山医院胡洁教授:早期非小细胞肺癌精准医疗的展望
Liquid Biopsy in Monitoring Dynamic Changes of Driver Genes in Advanced NSCLC
广东省人民医院周清教授:液体活检在晚期非小细胞肺癌驱动基因动态监测中的作用
New Clinical Trials on Gene Alteration in China
上海胸科医院陆舜教授:中国针对基因突变的最新临床试验
Meet the Expert (MTE09) (Ticketed Session: €35,00)
·Biomarkers for Targeted Therapies and Immune Checkpoint Inhibitors in Advanced NSCLC
专家见面会:晚期NSCLC靶向和免疫抑制剂生物标志物
专家:王洁教授、Sabine Z?chbauer教授
时间:12月5日 07:30 - 08:30
地点: Stolz 1
Science Session (SC05): Novel Drugs in Thoracic Cancers
·Novel Tyrosine Kinase Inhibitors in Lung Cancer
肺癌治疗的新一代TKI
讲者:上海市肺科医院周彩存教授
时间:12月5日 11:40
地点: C2
Oral Session (OA07): Lymph Node Metastases and Other Prognostic Factors for Local Spread
·OA07.02: Omitting Intrapulmonary Lymph Node Retrieval May Affect the Oncological Outcome of pN0 Lung Cancer Patients: A Propensity Score Match Analysis
省去肺内淋巴结活检可能影响pN0肺癌患者的肿瘤学效果:倾向得分匹配分析
讲者:北京大学肿瘤医院吴楠
时间:12月5日 14:15 - 15:45
地点:Stolz 1
Mini Oral (MA02): RNA in Lung Cancer
·MA02.07: Evaluation of Exosomal miRNAs from Plasma as Potential Biomarker for NSCLC
讲者:温州医科大学附属第一医院金献测
时间:12月5日15:03
地点:Stolz 2
Science Session (SC09): Radiotherapy for a Global Cancer
· Radiotherapy in China
中国的肺癌放疗
讲者:中国医科院肿瘤医院王绿化教授
时间:12月5日17:00
地点:C8
Oral Session (OA08): Targeted Therapies in Brain Metastases
·OA08.01: Exploration of the Underlying Mechanisms of Leptomeningeal Metastasis in NSCLC Patients through NGS of Cerebrospinal Fluid
利用脑脊液二代测序技术探索非小细胞肺癌患者软脑膜转移机制
讲者:浙江省肿瘤医院范云教授
时间:12月5日16:00
地点:Schubert 1
Mini Oral Session (MA04): HER2, P53, KRAS and Other Targets in Advanced NSCLC
·MA04.03: Preliminary Results of a Phase II Study about the Efficacy and Safety of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC
Pyrotinib 治疗HER2突变晚期非小细胞肺癌的II期试验
讲者:上海市肺科医院任胜祥教授
时间: 12月5日16:12
地点:Lehar 3-4
Mini Oral Session: (MA05): Innovative Techniques in Pulmonology and the Impact on Lung Cancer
·MA05.09: There is a Closely Relation between Exhaled Nitric Oxide and Radiation Pneumonitis
呼出的一氧化氮与放射性肺炎有密切关系
讲者:福建肿瘤医院李建成教授
时间:12月5日17:00
地点:Strauss 1
Mini Oral Session (MA06): Locally Advanced NSCLC: Risk Groups, Biological Factors and Treatment Choices
· MA06.06: Tumor Microenvironment and Brain Metastases in Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer
完全切除的IIIA(N2)非小细胞肺癌的肿瘤微环境及脑转移
讲者:天津医科大学肿瘤医院张瑾教授
时间:12月5日16:36
地点: Strauss 2
Plenary Session (PL03) Presidential Symposium主席论坛
·PL03.05: BRAIN: A Phase III Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201)
随机、开放、平行对照、多中心评价埃克替尼与全脑放疗治疗EGFR突变的晚期非小细胞肺癌脑转移患者的疗效和安全性III期BRAIN临床试验(CTONG 1201)
讲者:吴一龙教授
时间:12月6日09:25
地点:Hall D (Plenary Hall)
Science Session (SC15): Clinical Trials: How to set Priorities?
·The Chinese Perspective
临床试验之中国视角
讲者:吴一龙教授
时间:12月6日11:30
地点:C8
Oral Session (OA09): Locally Advanced NSCLC: Innovative Treatment Strategies
·OA09.03: Randomized Controlled Study Comparing Adjuvant versus Neo-Adjuvant Chemotherapy in Resectable Stage IB to IIIA NSCLC
对比可切除IB期-IIIA期非小细胞肺癌的辅助与新辅助化疗的随机对照试验
讲者:吴一龙教授
时间:12月6日11:20
地点:Strauss 3
Oral Session (OA09): Locally Advanced NSCLC: Innovative Treatment Strategies
·OA09.07: Individual Isotoxic RT Dose Escalation Based on V20 and Advanced Technologies Benefit Stage III NSCLC Treated with CCRT
讲者:山东省肿瘤医院李宝生教授
时间:12月6日12:05
地点:Strauss 3
Oral Session (OA11): Angiogenesis in Advanced Lung Cancer
·OA11.03: A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer
一项随机、多中心、呋喹替尼治疗晚期非小细胞肺癌的双盲II期研究
讲者:上海胸科医院陆舜教授
·OA11.07: Combining Anti-Angiogenesis and Immunotherapy Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer
抗血管生成和免疫治疗联合疗法增强免疫反应以增加抗肿瘤效果
讲者:上海市肺科医院赵莎
时间:12月6日 11:00 - 12:30
地点:Stolz 2
Oral Session (OA12): SBRT and Other Issues in Early Stage NSCLC
·OA12.05: Noninvasive CT-Based Image Biopsy System (iBiopsy) for Early Stage Lung Adenocarcinoma
用于早期肺腺癌的基于CT图像的非侵入性活检技术(ibiopsy)
讲者:上海中山医院杨达伟
时间:12月6日11:45
地点: Strauss 2
Mini Oral Session (MA08): Treatment Monitoring in Advanced NSCLC
·MA08.03: Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma ctDNA Analysis
讲者:吴一龙教授
·MA08.07: Prospective Sequential Counts of Total CTC or cKIT+CTC in Advanced NSCLC with 1st Line Chemotherapy (POLICE)
讲者:吴一龙教授
时间:12月6日11:00 - 12:30
地点:Lehar 3-4
Mini Oral Session (MA11): Novel Approaches in SCLC and Neuroendocrine Tumors
·MA11.01: Molecular Profiling of Large Cell Neuroendocrine Carcinoma Using Capture-Based Targeted Sequencing
讲者:上海市胸科医院周真
·MA11.09: Progastrin-Releasing Peptide (ProGRP) to Rule out Progressive Disease in Patients with Small Cell Lung Carcinoma (SCLC)
讲者:北京协和医院张晓彤
时间:12月6日14:15 - 15:45
地点:Strauss 3
Science Session (SC16): Superior Sulcus Tumors
·Individualized Extended Lung Cancer Surgery: The Chinese Experience
个体化肺癌扩大切除手术之中国经验
讲者:周清华教授
时间:12月6日15:30
地点:Lehar 1-2
Science Session (SC17): Lung Cancer: A Global Cancer with Different Regional Challenges
·Lung Cancer in China: Challenges and Perspectives
中国肺癌治疗的挑战和前瞻
讲者:中山大学张力教授
时间:12月14:45
地点: Strauss 1
Science Session (SC23): The Importance of Co-Operative Groups
·Cooperative Groups in China: The CSCO Experience
中国的CSCO经验
讲者:广东省人民医院周清教授
时间:12月6日16:45
地点: Strauss 3
Meet the Expert (MTE21) (Ticketed Session: €35,00)
·Next Generation Sequencing
专家见面会:下一代测序
专家:美国Ignacio Wistuba教授、上海肺科医院李雪飞
时间:12月7日07:30 - 08:30
地点: Schubert 1
Meet the Expert (MTE26) (Ticketed Session: €35,00)
·EGFR Targeted Therapies: Lessons Learned
专家见面会:EGFR 靶向治疗经验
专家:陆舜教授、Frederico Cappuzzo教授
时间:12月7日07:30 - 08:30
地点: Schubert 6
Educational Session (ED12): Regional Tobacco Control Policies: Advances & Challenges
·Tobacco Control Policies in China
中国的控烟政策
讲者:首都医科大学宣武医院支修益教授
时间:12月7日11:45 -
地点: C7
Oral Session (OA19): Translational Research in Early Stage NSCLC
·OA19.03: Identify Lung Adenocarcinoma in Situ among Pulmonary Micro-Nodules
through Blood Gene Expression Profiles
通过血液基因表达谱在肺微结节中确定肺部原位腺癌
讲者:上海交通大学附属胸科医院韩宝惠教授
时间:12月7日11:20
地点: Schubert 3
Oral Session (OA21): Palliative and Supportive Care for Lung Cancer Patients
·OA21.01: Pooled Analysis of the Incidence and Risk of Treatment-Related Pneumonitis with Anti-PD-1/PD-L1 Therapies in Cancer Patients
癌症患者抗PD-1/PD-L1治疗相关性肺炎的发生率和风险集合分析
讲者:中山大学附属肿瘤医院洪少东
时间:12月7日11:00
地点: Schubert 5
Mini Oral Session (MA15): Immunotherapy Prediction
·MA15.03: The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD-1 Blockade in Advanced NSCLC
Weijing Cai
·MA15.10: Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong
时间:12月7日14:15 - 15:45
地点: Schubert 1
Mini Oral Session (MA16): Novel Strategies in Targeted Therapy
·MA16.06: Phase I/II Study of AC0010, Mutant-Selective EGFR Inhibitor, in Non-Small
·Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation
第三代EGFR抑制剂AC0010治疗T790M突变的非小细胞肺癌的I / II期研究
讲者:广东省人民医院吴一龙教授
时间:12月7日14:51
地点: Strauss 2
Mini Oral Session (MA17): Genetic Drivers
·MA17.05: Evolutionary Trajectories of Molecular Progression in Different Subtypes of Primary Lung Adenocarcinomas
讲者:广东省人民医院翟浩然
·MA17.11: Knockdown of Akt2 Suppresses Tumorigenesis and Raf1 Overexpression Offsets This Effect in Non-Small Cell Lung Cancer
讲者:四川大学华西医院赵爽
时间:12月 7日 14:15 - 15:45
地点:Lehar 1-2